Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-03-29
1998-06-09
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 21, 536122, 5361231, 536124, 514 54, 514 56, 514921, A61K 31725, C08B 3710
Patent
active
057634270
ABSTRACT:
The present invention provides compositions and methods for inactivating thrombin bound to fibrin within a thrombus or clot, whereby the ability of clot-bound thrombin to catalytically promote further clot accretion is substantially diminished or eliminated. The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.
REFERENCES:
patent: 4281108 (1981-07-01), Fussi
patent: 4351938 (1982-09-01), Barnett
patent: 4496550 (1985-01-01), Lindahl et al.
patent: 4500519 (1985-02-01), Lormeau et al.
patent: 4629699 (1986-12-01), Bianchini
patent: 4687765 (1987-08-01), Vairel et al.
patent: 4791195 (1988-12-01), Bianchini
patent: 4847338 (1989-07-01), Linhardt et al.
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 4933326 (1990-06-01), Bianchini et al.
patent: 4942156 (1990-07-01), Foley et al.
patent: 4981955 (1991-01-01), Lopez
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5013724 (1991-05-01), Petitou et al.
patent: 5019649 (1991-05-01), Lormeau et al.
patent: 5039529 (1991-08-01), Bergendahl et al.
patent: 5084564 (1992-01-01), Vila et al.
patent: 5106734 (1992-04-01), Nielsen
patent: 5236910 (1993-08-01), Egidio et al.
patent: 5547944 (1996-08-01), Mascellani et al.
Alhenc-Gelas, et al., "Laboratory Control of Low-Molecular-Weight Heparins: Needs and Possibilities," Fundamental and Clinical Cardiology, 19:43-54 (1994).
Atha, et al., "Physicochemical Characterization of Low Molecular Weight Heparin," J. Pharm. Sciences, 84(3):360-364 (Mar. 1995).
Barzu, et al., "O-Acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase .alpha.-smooth muscle active expression in cultured arterial smooth muscle cells," Euro. J. Pharm., 219:225-233 (1992).
Barzu, et al., "Preparation and Anti-HIV Activity of O-Acylated Heparin and Dermatan Sulfate Derivatives with Low Anticoagulant Effect," J. Med. Chem., 36:3546-3555 (1993).
Cifonelli, et al., "The Distribution of 2-Acetamido-2-Deoxy-D-glucose residues in Mammalian Heparins," Charbo. Res., 21:173-186 (1972).
Doctor, et al., "Anticoagulant Properties of Semisynthetic Polysaccharide Sulfates," Thrombosis Research, 64:413-425 (1991).
Horton, et al., The Nitrous Acid Deamination of Glycosides and Acetates of 2-Amino-2-Deoxy-D-Glucose, Charbo. Res., 30:367-374 (1973).
Jordan, et al., "The Kinetics of Hemostatic Enzyme-Antithrombin Interactions in the Presence of Low Molecular Weight Heparin," J. of Biol. Chem., 255(21):10081-10090 (1980).
Lagunoff, et al., "Determination of 2-Deopxy-2-Sulfoaminohexose Content of Mucopolysaccharides," Archives of Biochem. and Biophys., 99:396-400 (1962).
Lindhardt, et al., "Oligosaccharide Mapping of Low Molecular Weight Heparins: Structure and Activity Differences," J. Med. Chem., 33:1639-1645 (1990).
Mascellani, et al., Active Sites of Dermatan Sulfate for Heparin Cofactor II. Isolation of a Nonasaccharide Fragment Containing Four Disaccharide (1,3)-.beta.-D-N-Acetylgalactosamine 4-Sulfate!, J. Carbohydrate Chem., 14(8):1165-1177 (1995).
Mattsson, et al., "Antithrombotic Effects of Heparin Oligosaccharides," Annals of the N.Y. Acad. Sci., 556:323-332 (1989).
Nagase, et al., "Depolymerized Holothurian Glycosaminoglycan With Novel Anticoagulant Actions: Antithrombin III-and Heparin Cofactor II-Independent Inhibition of Factor X Activation by Factor IXa-Factor VIIIa Complex and Heparin Cofactor II-Dependent Inhibition of Thrombin," Blood, 85(6):1527-1534 (1995).
Schoen, et al., "The Effect of Sulfation of the Anticoagulant and Antithrombin III-Binding Properties of a Heparin Fraction with Low Affinity for Antithrombin III," Thrombosis Research, 57:415-423 (1990).
Shimotori, et al., "Comparative Studies of Heparin Cofactor Activity Toward Antithrombin III and Heparin Cofactor II, and Antithrombin III Affinity Between Low Molecular Weight heparin and Unfractionated Heparin," Seminars in Thrombosis and Hemostasis, 16 (supp.):71-76 (1990).
Shively, et al., "Formation of Anhydrosugars in the Chemical Depolymerization of Heparin," Biochemistry, 15(18):3932-3942 (1976).
Shively, et al., "Nearest Neighbor Analysis of Heparin: Identification and Quantitation of the Products Formed by Selective Depolymerization Procedures," Biochemistry, 15(18):3943-3950 (1976).
Shively, et al., "Stoichiometry of the Nitrous Acid Deaminative Cleavage of Model Amino Sugar Glycosides and Glycosaminoglycuronans," Biochemistry, 9(1):33-43 (1970).
Svahn, et al., "Inhibition of angiogenesis by heparin fragments in the presence of hydrocortisone," Carbohydrate Polymers, 18:9-16 (1992).
Tollefsen, et al., "Effect of Low Molecular Weight Heparin Preparations on the Inhibition of Thrombin by Heparin Cofactor II," Seminars in Thrombosis and Hemostasis, 16 (supp.):66-70 (1990).
Weitz, et al., "New Anticoagulant Strategies," J. Lab. Clin. Med., 122(4):364-373 (1993).
Cade, et al., "A Comparison of the Antithrombotic and Haemorrhagic Effects of Low Molecular Weight Heparin Fractions: The Influence of the Method of Preparation," Thrombosis Research, 35:613-625 (1984).
The Merck Index, Twelfth Edition; S. Budavari et al., eds.; Merck & Co., Inc., 1996, Whitehouse Station, New Jersey; monograph 4685.
Hirsh Jack
Weitz Jeffrey I.
Young Edward
Fonda Kathleen K.
Hamilton Civic Hospitals Research Development Inc.
LandOfFree
Compositions and methods for inhibiting thrombogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting thrombogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting thrombogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199262